CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary treatment for lymphoma, a type of blood cancer affecting the lymphatic system. This therapy harnesses the patient’s own immune system by collecting T-cells, genetically modifying them to recognize and attack cancer cells, and then reintroducing them into the body. CAR-T therapy is particularly effective for patients with relapsed or refractory B-cell lymphoma who have not responded to conventional treatments. The procedure is personalized, cutting-edge, and performed in specialized medical centers with advanced facilities.

Before undergoing CAR-T therapy, patients go through a comprehensive evaluation to ensure the treatment is safe and effective. This preparation phase includes detailed medical assessments, laboratory tests, and imaging scans to confirm the type and stage of lymphoma.

Patients may also undergo a short course of chemotherapy, called conditioning therapy, to prepare the body for the infusion of CAR-T cells. During this period, doctors discuss the treatment process, potential side effects, and recovery expectations to ensure patients and their families are fully informed.

Key steps before the procedure may include:

• Detailed blood tests and organ function evaluation
• Imaging scans such as CT, PET, or MRI
• Lymph node or bone marrow biopsy if required
• Pre-treatment counseling about risks, benefits, and expected outcomes
   

CAR-T therapy is a highly specialized treatment that uses the patient’s own immune cells to target cancer. The therapy involves several critical steps to ensure safety and effectiveness:

• T-Cell Collection: Patient’s T-cells are collected via apheresis
• Genetic Modification: T-cells are engineered to recognize lymphoma cells
• Cell Expansion: Modified cells are multiplied in a lab
• Conditioning Therapy: Short chemotherapy prepares the body for infusion
• Infusion: CAR-T cells are infused back to attack cancer cells